{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:55:17Z","timestamp":1789750517763,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.esmoop.2026.106905","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:28:09Z","timestamp":1773937689000},"page":"106905","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":false,"given":"H.S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"J.","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6591-3367","authenticated-orcid":false,"given":"F.","family":"Marm\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9501-4509","authenticated-orcid":false,"given":"E.","family":"de Azambuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2303-2764","authenticated-orcid":false,"given":"J.","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8490-9064","authenticated-orcid":false,"given":"Y.","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6364-5431","authenticated-orcid":false,"given":"C.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bardia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.esmoop.2026.106905_bib2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.106905_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.5858\/arpa.2023-0950-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer","volume":"147","author":"Wolff","year":"2023","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.esmoop.2026.106905_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2025.100567","article-title":"Capturing breast cancer subtypes in cancer registries: insights into real-world incidence and survival","volume":"44","author":"Vaz-Gon\u00e7alves","year":"2025","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.esmoop.2026.106905_bib5","series-title":"Prescribing information","year":"2025"},{"key":"10.1016\/j.esmoop.2026.106905_bib6","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.esmoop.2026.106905_bib9","author":"Chang"},{"issue":"16","key":"10.1016\/j.esmoop.2026.106905_bib10","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.esmoop.2026.106905_bib11","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1200\/JCO.22.01002","article-title":"Sacituzumab govitecan in hormone receptor-positive\/human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10411","key":"10.1016\/j.esmoop.2026.106905_bib12","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.esmoop.2026.106905_bib13","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1038\/s41591-024-03269-z","article-title":"Sacituzumab govitecan in HR+HER2- metastatic breast cancer: the randomized phase 3 EVER-132-002 trial","volume":"30","author":"Xu","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106905_bib14","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int J Cancer"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106905_bib15","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.21037\/atm-21-2763","article-title":"Assessment of racial differences in the incidence of thrombocytopenia induced by trastuzumab emtansine: a systematic review and meta-analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106905_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102090","article-title":"Racial differences in cutaneous events among patients receiving enfortumab vedotin","volume":"22","author":"Vlachou","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"26","key":"10.1016\/j.esmoop.2026.106905_bib17","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.esmoop.2026.106905_bib18","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1002\/cncr.30789","article-title":"Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics","volume":"123","author":"Ocean","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2026.106905_bib19","series-title":"Medical Genetics Summaries","article-title":"Irinotecan therapy and UGT1A1 genotype","author":"Dean","year":"2012"},{"key":"10.1016\/j.esmoop.2026.106905_bib20","first-page":"61","article-title":"UGT1A1 polymorphisms in cancer: impact on irinotecan treatment","volume":"10","author":"Takano","year":"2017","journal-title":"Pharmgenomics Pers Med"},{"issue":"2","key":"10.1016\/j.esmoop.2026.106905_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/tpj.2013.10","article-title":"Association of UGT1A1\u221728 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians","volume":"14","author":"Liu","year":"2014","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.esmoop.2026.106905_bib22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2026.106905_bib23","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2024.42.16_suppl.3029","article-title":"Pooled safety analysis of sacituzumab govitecan (SG) in multiple solid tumor types","volume":"42","author":"Rugo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106905_bib24","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1111\/cts.13277","article-title":"Association of UGT1A1\u22176, UGT1A1\u221728, or ABCC2 c.3972C>T genetic polymorphisms with irinotecan-induced toxicity in Asian cancer patients: meta-analysis","volume":"15","author":"Atasilp","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.esmoop.2026.106905_bib25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3390\/cancers13071566","article-title":"UGT1A1 guided cancer therapy: review of the evidence and considerations for clinical implementation","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.esmoop.2026.106905_bib26","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.106905_bib27","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s10147-024-02589-x","article-title":"Preliminary results from ASCENT-J02: a phase 1\/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors","volume":"29","author":"Naito","year":"2024","journal-title":"Int J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.106905_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106905_bib29","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.21037\/gs.2020.03.26","article-title":"Does ethnicity matter in chemotherapy for breast cancer?","volume":"9","author":"Komorowski","year":"2020","journal-title":"Gland Surg"},{"issue":"5","key":"10.1016\/j.esmoop.2026.106905_bib30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.esmoop.2026.106905_bib31","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.ejca.2010.02.049","article-title":"Dose-dependent association between UGT1A1\u221728 polymorphism and irinotecan-induced diarrhoea: a meta-analysis","volume":"46","author":"Hu","year":"2010","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2026.106905_bib32","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00280-014-2382-3","article-title":"UGT1A1\u22176 polymorphisms are correlated with irinotecan-induced toxicity: a system review and meta-analysis in Asians","volume":"73","author":"Cheng","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106905_bib33","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-014-2405-0","article-title":"Associations between UGT1A1\u22176 or UGT1A1\u22176\/\u221728 polymorphisms and irinotecan-induced neutropenia in Asian cancer patients","volume":"73","author":"Han","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.106905_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/cpt.269","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for UGT1A1 and atazanavir prescribing","volume":"99","author":"Gammal","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"14","key":"10.1016\/j.esmoop.2026.106905_bib35","first-page":"3723","article-title":"Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea","volume":"54","author":"Gupta","year":"1994","journal-title":"Cancer Res"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008471?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926008471?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:12:07Z","timestamp":1777623127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926008471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2059702926008471"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106905","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacituzumab govitecan in patients with metastatic breast cancer: pooled safety analysis of data from patients in North America, Europe, and Asia","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.106905","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"106905"}}